Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 24;24(7):6123.
doi: 10.3390/ijms24076123.

Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease

María Del Barrio  1 , Lucía Lavín  2 , Álvaro Santos-Laso  1 , Maria Teresa Arias-Loste  1 , Aitor Odriozola  1 , Juan Carlos Rodriguez-Duque  1 , Coral Rivas  1 , Paula Iruzubieta  1 , Javier Crespo  1
Affiliations
Review

Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease

María Del Barrio et al. Int J Mol Sci. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an increase in intestinal permeability seem to be key in the development and progression of NAFLD. Therefore, the manipulation of microbiota seems to provide a promising therapeutic strategy. One way to do so is through faecal microbiota transplantation (FMT). Here, we summarize the key aspects of FMT, detail its current indications and highlight the most recent advances in NAFLD.

Keywords: dysbiosis; faecal microbiota transplantation; gut microbiota; non-alcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different ways to manipulate gut microbiota.
Figure 2
Figure 2
Non-alcoholic-fatty-liver-disease (NAFLD)-related dysbiosis and increased intestinal permeability and the utility of faecal microbiota transplantation (FMT). The increase in intestinal permeability enables bacteria and their metabolites to reach the liver through the portal system. In FMT, a stool sample is taken from a healthy donor. After processing, it will be administered to the receptor subject with NAFLD. The FMT can be performed in different ways, either orally or by endoscopy or enemas. FMT is intended to reverse existing dysbiosis and restore the intestinal barrier, and consequently improve the severity of the disease.
See this image and copyright information in PMC

References

    1. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431. - DOI - PubMed
    1. Le M.H., Yeo Y.H., Li X., Li J., Zou B., Wu Y., Ye Q., Huang D.Q., Zhao C., Zhang J., et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2022;20:2809–2817.e28. doi: 10.1016/j.cgh.2021.12.002. - DOI - PubMed
    1. El-Kassas M., Cabezas J., Coz P.I., Zheng M.-H., Arab J.P., Awad A. Nonalcoholic Fatty Liver Disease: Current Global Burden. Semin. Liver Dis. 2022;42:401–412. doi: 10.1055/a-1862-9088. - DOI - PubMed
    1. Estes C., Anstee Q.M., Arias-Loste M.T., Bantel H., Bellentani S., Caballeria J., Colombo M., Craxi A., Crespo J., Day C.P., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 2018;69:896–904. doi: 10.1016/j.jhep.2018.05.036. - DOI - PubMed
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. J. Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2015.11.004. - DOI - PubMed